Drug Monograph

Drug Name: **Dupixent® (dupilumab) pre-filled pen**
Drug Class: **Monoclonal Antibodies**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Dupixent is now available as a single-dose prefilled pen containing 300 mg/2 mL dupilumab
Manufacturer:	Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
Indications:	1) Treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable 2) As an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma
Costs:	$1, 555.04 per pen Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☐ Open Access ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☒ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: Megan Fast, PharmD
Date: August 5, 2020